Clinical trial
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
NCT01774578
Study timeline
Study start (unknown)2013-02-01Date precision: month
Registry last updated2020-05-28
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non-small Cell Lung Cancerunresolved
Non-small Cell Lung Cancer Recurrentunresolved
Interventions
DocetaxelDRUG · verified · RxNorm: docetaxel
HyperAcute®-Lung ImmunotherapyBIOLOGICAL
GemcitabineDRUG · verified · RxNorm: gemcitabine
PemetrexedDRUG · verified · RxNorm: pemetrexed
Sponsors & collaborators
NewLink Genetics Corporationlead sponsor
Mapped research locations
ChicagoIllinois, United States2St LouisMissouri, United States1ClevelandOhio, United States1CincinnatiOhio, United States1ColumbusOhio, United States1IndianapolisIndiana, United States1OmahaNebraska, United States1Winston-SalemNorth Carolina, United States1Kansas CityMissouri, United States1MadisonWisconsin, United States1GainesvilleFlorida, United States1KnoxvilleTennessee, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01774578 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.